Letter

A/H1N1 flu pandemic

Roche responds

BMJ 2009; 339 doi: 10.1136/bmj.b3758 (Published 14 September 2009)
Cite this as: BMJ 2009;339:b3758

Access to the full text of this article requires a subscription or payment. Please log in or subscribe below.

  1. Michelle Rashford, medical director1
  1. 1Roche Products, Welwyn Garden City, Hertfordshire AL7 1TW
  1. michelle.rashford{at}roche.com

    The use of oseltamivir (Tamiflu) in children and the development of resistance from widespread usage have been much debated.1

    Antiviral treatments are currently the only available therapeutic option to prevent and treat infection with the A/H1N1 flu virus. The product summary for oseltamivir shows that it is effective and well tolerated in children.

    The …

    Access to the full text of this article requires a subscription or payment

    Subscribe

    Article access

    Article access for 1 day

    Purchase this article for £20 $30 €32*

    The PDF version can be downloaded as your personal record

    * Prices do not include VAT

    Rapid responses

    THIS WEEK'S POLL

    BMJ most popular